What's the latest with investigational drugs for soft tissue sarcoma?

Elena CojocaruAndrea NapolitanoCyril FisherPaul H Huang Robin L JonesKhin Thway

Published in: Expert opinion on investigational drugs (2022)

Immune-oncology drugs (IOs) show promise in certain subtypes of STS, but it is recognized that PD-1/PD-L1 axis inhibition is not enough on its own. Better trial stratifications based on the molecular categorization of different subtypes of STS are needed, and more evidence suggests that 'one size fits all' treatment is no longer sustainable in this heterogeneous and aggressive group of tumors.

Keyphrases

phase ii
palliative care
study protocol
phase iii
big data
drug induced
single molecule
artificial intelligence